DuPont Spun Chemours Off in 2015. Eleven Years On, Both Are Named in the Same Order.
- Chief Judge Renée Marie Bumb of the US District Court for New Jersey approved settlements worth more than $2.5 billion on 7 August 2026, resolving claims first filed in 2019 against DuPont, Chemours, Corteva and 3M. The settlements themselves were announced in mid-2025; what happened on Friday was judicial approval, not a new agreement.
- DuPont, Chemours and Corteva will pay $875 million over 25 years for natural resource and other damages, clean up four former New Jersey industrial sites including Chambers Works in Salem County, and create a $1.2 billion remediation fund. 3M will pay $400 million to $450 million across the same period, for drinking water contamination claims.
- The named defendants include The Chemours Company and Chemours Company FC, both of which DuPont spun off in 2015, alongside EIDP, DuPont Specialty Products USA, Corteva and DuPont de Nemours. The settlements resolve site litigation, statewide aqueous film-forming foam claims, and obligations under the state’s Statewide PFAS Directive.
- Bumb overruled objections from Carneys Point Township and the Borough of Sayreville, which argued New Jersey lacked authority to resolve claims belonging to individual municipalities. 3M said it was pleased and noted that it exited all PFAS manufacturing last year. New York’s attorney general filed a comparable action in July 2026.
CI read
The settlement is not the news and neither is the number. DuPont separated its performance chemicals business into Chemours in 2015, and eleven years later DuPont de Nemours, Chemours, Chemours FC, DuPont Specialty Products and Corteva all appear in the same order, paying into the same funds. The corporate separation did not sever the liability. Any executive team contemplating a structural answer to a legacy exposure problem should read that sentence twice, because healthcare has been running the same play for years.
- The read-across is to healthcare, not to chemicals. Liability-driven separations are a standing feature of this industry, and this order is a data point on whether they hold. A spin-off transfers assets and contracts. It does not reliably transfer joint exposure for conduct that predates it, particularly where a state pleads natural resource damage rather than product liability, and particularly where the parent retained a specialty products entity that stayed in the caption. Anyone modelling a legacy liability that has been placed inside a separated entity should discount the separation rather than the claim.
- The municipal objection is the precedent, and it went the state’s way. Carneys Point and Sayreville argued that New Jersey could not settle claims belonging to individual municipalities, and Bumb overruled them. That is a ruling on whether a state attorney general can bind subordinate public entities inside a global environmental settlement, and it makes state-level resolution substantially more attractive to defendants than a fragmented municipal fight. Expect it cited in the New York action filed last month, and expect defendants to prefer the venue that produced it.
- What this means for medical supply chains, which nobody is writing about. 3M states it exited PFAS manufacturing entirely last year. Fluoropolymers derived from that chemistry sit throughout medical device manufacturing and single-use bioprocessing, in graft materials, tubing, container closures and filtration components. So the environmental liability has already produced a supply consequence upstream of medtech and biopharma, before any product liability theory has been tested in court. The number worth tracking is not the settlement total. It is how many fluoropolymer grades remain qualified for implantable and bioprocessing use once the producers with the deepest pockets have left the category.
Read the original source (New Jersey Office of the Attorney General) →